The RTS,S Clinical Trials Partnership reports the results of Phase 3 study of the efficacy, safety, and immunogenicity of a QS-21 containing candidate
malaria vaccine RTS,S/AS01 is being conducted in seven African countries.

RTSS_nejmoa1102287